AFP-positive liver cancer cells were significantly more sensitive to oxaliplatin (L-OHP) + epirubicin (EPI) + irinotecan + 5-fluorouracil (5-FU) and L-OHP + irinotecan + EPI. The gene discussed is AFP; the disease is liver cancer.